相关实验视频

Updated: May 11, 2025

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

夜间施用巴里西提尼布导致类风湿性关节炎的快速药物反应:一项多中心非随机对照研究

Teppei Hashimoto¹, Kazuyuki Tsuboi², Takeo Abe¹

¹Department of Diabetes, Endocrinology and Clinical Immunology, School of Medicine, Hyogo Medical University, Nishinomiya, Japan.

Arthritis research & therapy

|April 17, 2025

概括

与早晨剂量相比,晚上服用巴里西提尼布,特别是4mg,显著改善了类风湿性关节炎症状. 这种慢性治疗方法提高了炎症状况的治疗反应.

科学领域:

类风湿病学类风湿病学
药理学药理学是指药理学的学科.
时间生物学时间生物学

背景情况:

类风湿性关节炎 (RA) 患者血清显示炎症性细胞因子水平昼夜节律,夜晚到清晨达到峰值.
在RA中,细胞因子动力学是经过验证的治疗标.
这项研究研究了基于细胞因子分泌模式的晚上巴里西提尼布治疗RA的治疗方法.

研究的目的:

为了评估晚上和早上巴里西提尼布在类风湿性关节炎患者的疗效.
评估慢性治疗对炎症性细胞因子分泌和疾病活性的影响.
为了确定巴里西提尼布在 RA 管理中的最佳剂量时间.

主要方法:

这是一项为期52周的多中心,非随机对照研究,涉及122名RA患者.
患者被分为四组:巴里西提尼布2毫克或4毫克,在早上或晚上服用.
主要终点:第12周的ACR20 二级终点:ACR50/70,CDAI的变化. 这是一个很好的结果. 使用了倾向性得分权重.

主要成果:

晚上4毫克剂量 (BAR4EVE) 显示出明显更好的ACR20改善比早上4毫克剂量 (BAR4MORN) (78.2%对43.3%).
与BAR4MORN相比,BAR4EVE表现出更好的ACR20/50/70反应和更大的CDAI降低.
虽然在2mg晚上 (BAR2EVE) 和早上 (BAR2MORN) 剂量之间没有发现主要终点的显著差异,但随着时间的推移,BAR2EVE显示了ACR20/50的改善.

结论:

晚上服用巴里西提尼布,特别是4毫克,可增强类风湿性关节炎的治疗反应.
针对细胞因子分泌节律的慢疗提供了快速的药物反应.
这表明JAK抑制剂在长期治疗策略中的新应用.

关键词:

巴里西提尼布 (Baricitinib) 是一种药物.时间疗法 (Chronotherapy) 是一种时间疗法.这是一种JAK抑制剂.类风湿性关节炎类风湿性关节炎类风湿性关节炎

更多相关视频

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass

Published on: July 14, 2023

Knee Arthrocentesis in Adults

Knee Arthrocentesis in Adults

Published on: February 25, 2022

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...